EA Pharma in the news
Natural health and wellness
Tamtam found 16 recent articles about EA Pharma.
- EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan
EA Pharma is starting a Phase 3 trial in Japan for a schizophrenia treatment targeting patients who are resistant to current medications.
- Une nouvelle acquisition à l'international pour le groupe azuréen Olyos, ex-EA Pharma
Olyos, formerly EA Pharma, acquired Chilean firm Newscience to expand its international footprint in the natural health and nutraceutical market.
- EAFIT: A Dietitian’s Opinion (2023)
EAFIT, a sports nutrition brand by EA Pharma, is a market leader in French pharmacies, manufacturing most products in France but lacking transparency on raw material origins.
- Ensho emerges with inflammatory disease portfolio from Eisai's EA Pharma
Ensho Therapeutics has launched to develop an oral ulcerative colitis drug acquired from EA Pharma, with a phase 2 trial planned for early next year.
- Compléments alimentaires : le laboratoire EA Pharma va changer d’actionnaire
Laboratory EA Pharma is undergoing a change in its ownership and shareholders.
- EA Pharma se refinance
EA Pharma is refinancing its debt to fund new international acquisitions like the Italian company Stardea.
- EA Pharma poursuit son développement à l’international avec l’acquisition du Groupe W et annonce la création d’Olyos Group
EA Pharma has acquired the US-based W Group and established Olyos Group to expand its natural health and supplement business into the American market.
- EA Pharma continues its international expansion with the acquisition of Groupe W and announces the creation of Olyos Group
Natural health specialist EA Pharma has acquired the American W Group and established Olyos Group to expand its dietary supplement business into the US market.
- Le laboratoire EA Pharma fait le plein de vitamines en Europe
EA Pharma is accelerating its European expansion through the acquisition of Stardea and a focus on natural health products to reach 100 million euros in revenue.
- Le groupe EA Pharma acquiert l’italien Stardea
EA Pharma is expanding its European presence in natural health by acquiring the Italian supplement and dermocosmetics firm Stardea.
- EA Pharma acquiert Stardea et poursuit son expansion européenne
EA Pharma acquired the Italian laboratory Stardea to strengthen its position in the European food supplement and nutraceutical market.
- EA Pharma entame son expansion internationale par l’Espagne
EA Pharma expands into the Spanish market by acquiring Drasanvi, a health supplement and natural cosmetics provider, boosting total revenue to 70 million euros.
- Pourquoi EA Pharma accélère à l’international
EA Pharma is expanding internationally through the acquisition of Spanish nutraceutical company Drasanvi and targeting European markets to become a leader in natural health and nutrition.
- MOVICOL® Launched in Japan
Launched the first polyethylene glycol-based chronic constipation treatment in Japan for adults and children.
- Eisai pairs with Ajinomoto to form GI specialist EA Pharma
Eisai and Ajinomoto have merged their gastrointestinal pharmaceutical divisions to create EA Pharma, a new company specializing in GI therapies.
- THE GASTROINTESTINAL DISEASE BUSINESS OF EISAI CO., LTD. AND
Eisai's gastrointestinal business is merging with Ajinomoto Pharmaceuticals to create EA Pharma, a new company focused on gastrointestinal diseases.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like EA Pharma?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies